...
首页> 外文期刊>Gene Therapy and Molecular Biology >Retrovirally-mediated genetic correction of mesenchymal stem cells from patients affected by mucopolysaccharidosis type II (Hunter Syndrome)
【24h】

Retrovirally-mediated genetic correction of mesenchymal stem cells from patients affected by mucopolysaccharidosis type II (Hunter Syndrome)

机译:逆转录病毒介导的II型粘多糖贮积症(亨特综合征)患者间充质干细胞的基因校正

获取原文
           

摘要

Mucopolysaccharidosis type II (MPSII) is an X-linked metabolic storage disorder due to the deficiency of iduronate-2-sulphatase (IDS) and accumulation of glycosaminoglycans (GAGs). Clinically it presents as a multi- system disorder with developmental delay, bone and joint disease and in the severe forms progressive mental retardation. At present little therapeutic options are available. Bone marrow transplantation is no longer recommended due to the severe side effects and lack of proven efficacy in correcting central nervous system and bone disease. Enzyme replacement therapy is under assessment and it requires weekly, expensive administration for the lifespan of the individual. Mesenchymal stem cells (MSC) are bone marrow-derived cells capable of differentiation into tissue such as bone and have been shown to contribute to bone repair. They are amenable to gene manipulation and therefore provide an excellent target for the correction of MPSII disease, especially with regard to bone disease. In this study we tested whether MSC from MPSII patients (hMSCMPSII) could be corrected with a retroviral vector expressing the IDS gene. Following transduction hMSCMPSII maintained the capacity to differentiate into osteoblasts and adipocytes and showed levels of IDS enzyme over 10 fold higher than those detected in MSC from healthy donors. This led to normalization of GAGs storage in hMSCMPSII. Such transduced cells were able to cross-correct MPSII fibroblasts by uptake of the IDS enzyme via the mannose-6-phosphate receptor. This study suggests that correction of autologous hMSCMPSII by retroviral gene transfer is effective and may be amenable for the improvement of the skeletal features of the disease.
机译:II型粘多糖贮积病(MPSII)是X连锁代谢存储障碍,归因于缺乏氨基葡萄糖-2-硫酸酯酶(IDS)和糖胺聚糖(GAG)的积累。在临床上,它表现为具有发育延迟,骨骼和关节疾病的多系统疾病,并以严重形式进行性智力低下。目前很少有治疗选择。由于严重的副作用以及缺乏纠正中枢神经系统和骨病的有效方法,不再推荐进行骨髓移植。酶替代疗法正在评估中,并且需要在个人的生命周期内每周进行昂贵的管理。间充质干细胞(MSC)是骨髓来源的细胞,能够分化成组织,例如骨骼,并已被证明有助于骨骼修复。它们适用于基因操作,因此为纠正MPSII疾病(尤其是骨疾病)提供了极好的靶标。在这项研究中,我们测试了MPSII患者的MSC(hMSCMPSII)是否可以用表达IDS基因的逆转录病毒载体纠正。转导后,hMSCMPSII保持了分化为成骨细胞和脂肪细胞的能力,并显示出IDS酶的水平比健康捐献者的MSC中的IDS酶高10倍以上。这导致hMSCMPSII中GAG存储的规范化。这样的转导细胞能够通过经由6-磷酸甘露糖受体摄取IDS酶来交叉校正MPSII成纤维细胞。这项研究表明,通过逆转录病毒基因转移对自体hMSCMPSII进行校正是有效的,并且可以改善该疾病的骨骼特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号